Marinus van Marwijk Kooy

Isala — Netherlands

Medicine · Health Sciences

34h-index5.9kcitations86works9.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(27), Multiple Myeloma Research and Treatments(23), Lymphoma Diagnosis and Treatment(13), Hematopoietic Stem Cell Transplantation(9), Acute Lymphoblastic Leukemia research(9)

Publications84 total

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
Leukemia·2024· 9 citedOpen Access
Prognostic Value of <i>FLT3</i>-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia
Journal of Clinical Oncology·2022· 130 citedOpen Access
Poster: AML-234 Prognostic Value of FLT3-ITD Residual Disease in Acute Myeloid Leukemia
Clinical Lymphoma Myeloma & Leukemia·2022· 1 cited
AML-234 Prognostic Value of FLT3-ITD Residual Disease in Acute Myeloid Leukemia
Clinical Lymphoma Myeloma & Leukemia·2022· 1 citedOpen Access
P406: ENHANCED SIGNIFICANCE OF FLT3-ITD RESIDUAL DISEASE DETECTION ON TREATMENT OUTCOME IN ACUTE MYELOID LEUKEMIA
HemaSphere·2022Open Access
Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial
Blood Advances·2022· 105 citedOpen Access
Molecular characterization of mutant <i>TP53</i> acute myeloid leukemia and high-risk myelodysplastic syndrome
Blood·2022· 272 citedOpen Access
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Blood Advances·2021· 65 citedOpen Access
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
Cancers·2021· 14 citedOpen Access
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
Leukemia·2020Open Access
Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)
Journal of Clinical Oncology·2020· 83 citedOpen Access
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
The Lancet Haematology·2020· 378 citedOpen Access
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
Leukemia·2020· 23 citedOpen Access
Bortezomib-Based Transplantation and Consolidation Therapy Followed by Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma
SSRN Electronic Journal·2020Open Access
Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
Haematologica·2019· 34 citedOpen Access
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
New England Journal of Medicine·2018· 758 citedOpen Access
Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission
JCO Precision Oncology·2017· 34 citedOpen Access
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
Leukemia·2017· 197 citedOpen Access
GRAFT VERSUS LEUKEMIA EFFECT OF ALLOGENEIC STEM CELL TRANSPLANTATION AND MINIMAL RESIDUAL DISEASE IN PATIENTS WITH AML IN FIRST COMPLETE REMISSION
Pure Amsterdam UMC·2017· 2 cited
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML
Blood·2017· 96 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Pieter Sonneveld(18), Bob Löwenberg(17), Edo Vellenga(17), Bronno van der Holt(16), Jan J. Cornelissen(13), Okke de Weerdt(12), Gert J. Ossenkoppele(11), Mojca Jongen‐Lavrencic(11), Bart J. Biemond(11), Thomas Pabst(11), Pierre W. Wijermans(11), Marie José Kersten(11), Harry C. Schouten(10), Johan Maertens(10), Carlos Graux(9), Markus G. Manz(9), Peter J.M. Valk(9), Sonja Zweegman(9), Dimitri Breems(9), Leo F. Verdonck(8)